| scholarly article | Q13442814 |
| P356 | DOI | 10.1161/CIRCHEARTFAILURE.114.001218 |
| P8608 | Fatcat ID | release_w5jtyyjlqnanvgwih3577kte7q |
| P932 | PMC publication ID | 4303519 |
| P698 | PubMed publication ID | 25278000 |
| P50 | author | Brian L. Stauffer | Q48302717 |
| P2093 | author name string | Penny Nelson | |
| Carmen C Sucharov | |||
| Shelley D Miyamoto | |||
| Stephanie J Nakano | |||
| Matthew Movsesian | |||
| P2860 | cites work | Incidence, causes, and outcomes of dilated cardiomyopathy in children. | Q50791017 |
| Ser16 prevails over Thr17 phospholamban phosphorylation in the beta-adrenergic regulation of cardiac relaxation. | Q52979010 | ||
| Failure of low doses of amrinone to produce sustained hemodynamic improvement in patients with severe chronic congestive heart failure. | Q54465894 | ||
| Assessment of long-term therapy with milrinone and the effects of milrinone withdrawal | Q68858464 | ||
| Deficient production of cyclic AMP: pharmacologic evidence of an important cause of contractile dysfunction in patients with end-stage heart failure | Q68982799 | ||
| Systemic and coronary effects of intravenous milrinone and dobutamine in congestive heart failure | Q70032077 | ||
| Multicenter, double-blind study of intravenous milrinone for patients with acute heart failure in Japan. Japan Intravenous Milrinone Investigators | Q71513161 | ||
| Immunodetection of phosphorylation sites gives new insights into the mechanisms underlying phospholamban phosphorylation in the intact heart | Q71903446 | ||
| Decreased Catecholamine Sensitivity and β-Adrenergic-Receptor Density in Failing Human Hearts | Q72933722 | ||
| Isoforms of cyclic nucleotide phosphodiesterase PDE3A in cardiac myocytes | Q74558380 | ||
| Clinical features and outcomes of childhood dilated cardiomyopathy: results from a national population-based study | Q79372337 | ||
| Improved outcomes of pediatric dilated cardiomyopathy with utilization of heart transplantation | Q80356169 | ||
| Cardiac excitation-contraction coupling | Q28216347 | ||
| Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group | Q33157410 | ||
| Evaluation of a new bipyridine inotropic agent--milrinone--in patients with severe congestive heart failure | Q33482398 | ||
| Pharmacokinetics and side effects of milrinone in infants and children after open heart surgery | Q33501588 | ||
| Sarcoplasmic reticulum-associated cyclic adenosine 5'-monophosphate phosphodiesterase activity in normal and failing human hearts | Q34224951 | ||
| Outpatient continuous parenteral inotropic therapy as bridge to transplantation in children with advanced heart failure | Q36415090 | ||
| Phosphodiesterase type 3A regulates basal myocardial contractility through interacting with sarcoplasmic reticulum calcium ATPase type 2a signaling complexes in mouse heart | Q36630526 | ||
| Home inotropic therapy in children | Q36797958 | ||
| β-Adrenergic receptor antagonism in mice: a model for pediatric heart disease. | Q37235097 | ||
| cGMP-hydrolytic activity and its inhibition by sildenafil in normal and failing human and mouse myocardium | Q37312871 | ||
| Phosphodiesterase inhibition in heart failure | Q37355108 | ||
| Beta-adrenergic adaptation in paediatric idiopathic dilated cardiomyopathy. | Q37423781 | ||
| The impact of changing medical therapy on transplantation-free survival in pediatric dilated cardiomyopathy | Q37719083 | ||
| Carvedilol for children and adolescents with heart failure: a randomized controlled trial. | Q38395213 | ||
| Basal and isoprenaline-stimulated cAMP content in failing versus nonfailing human cardiac preparations | Q41847220 | ||
| Tachyphylaxis with amrinone therapy: association with sequestration and down-regulation of lymphocyte beta-adrenergic receptors | Q41955393 | ||
| Insulin-induced formation of macromolecular complexes involved in activation of cyclic nucleotide phosphodiesterase 3B (PDE3B) and its interaction with PKB. | Q42089521 | ||
| Cardiotonic Activity of Milrinone, a New and Potent Cardiac Bipyridine, on the Normal and Failing Heart of Experimental Animals | Q42243633 | ||
| Milrinone: systemic and pulmonary hemodynamic effects in neonates after cardiac surgery | Q42276649 | ||
| Milrinone and low cardiac output following cardiac surgery in infants: is there a direct myocardial effect? | Q42669384 | ||
| Prophylactic intravenous use of milrinone after cardiac operation in pediatrics (PRIMACORP) study. Prophylactic Intravenous Use of Milrinone After Cardiac Operation in Pediatrics | Q43843811 | ||
| Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial | Q43930568 | ||
| Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease | Q44324618 | ||
| Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study | Q44371716 | ||
| Yin Yang 1 is increased in human heart failure and represses the activity of the human alpha-myosin heavy chain promoter | Q44445863 | ||
| Hemodynamic and clinical benefits with intravenous milrinone in severe chronic heart failure: results of a multicenter study in the United States | Q44446042 | ||
| Isoforms of cyclic nucleotide phosphodiesterase PDE3 and their contribution to cAMP hydrolytic activity in subcellular fractions of human myocardium | Q46711233 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 1 | |
| P304 | page(s) | 57-63 | |
| P577 | publication date | 2014-10-02 | |
| P1433 | published in | Circulation: Heart Failure | Q2865806 |
| P1476 | title | Age-related differences in phosphodiesterase activity and effects of chronic phosphodiesterase inhibition in idiopathic dilated cardiomyopathy | |
| P478 | volume | 8 |
| Q92365643 | A PDE3A Promoter Polymorphism Regulates cAMP-Induced Transcriptional Activity in Failing Human Myocardium |
| Q57095323 | Acute isoproterenol leads to age-dependent arrhythmogenesis in guinea pigs |
| Q37742299 | Cardiac Adenylyl Cyclase and Phosphodiesterase Expression Profiles Vary by Age, Disease, and Chronic Phosphodiesterase Inhibitor Treatment |
| Q48308293 | Clinical management of dilated cardiomyopathy: current knowledge and future perspectives |
| Q89375106 | Differential Response to Heart Failure Medications in Children |
| Q64081792 | Elamipretide Improves Mitochondrial Function in the Failing Human Heart |
| Q48302617 | Exosomes from pediatric dilated cardiomyopathy patients modulate a pathological response in cardiomyocytes |
| Q50542706 | Fibrosis and Fibrotic Gene Expression in Pediatric and Adult Patients With Idiopathic Dilated Cardiomyopathy. |
| Q93241553 | From pediatrics to geriatrics: Mechanisms of heart failure across the life-course |
| Q39430716 | Genetics of paediatric cardiomyopathies |
| Q30235239 | Heart Failure in Pediatric Patients With Congenital Heart Disease |
| Q38678462 | Histone deacetylase adaptation in single ventricle heart disease and a young animal model of right ventricular hypertrophy |
| Q48410009 | Molecular Changes in Children with Heart Failure Undergoing Left Ventricular Assist Device Therapy |
| Q37047994 | Myocardial Response to Milrinone in Single Right Ventricle Heart Disease |
| Q37240681 | Natural History of Dilated Cardiomyopathy in Children |
| Q40625826 | Oral Enoximone as an Alternative to Protracted Intravenous Medication in Severe Pediatric Myocardial Failure |
| Q41068198 | Pediatric dilated cardiomyopathy hearts display a unique gene expression profile |
Search more.